// App-Quantinova.ai

9043 : A randomized, open label, phase II study comparing pemetrexed plus cisplatin followed by pemetrexed versus pemetrexed alone in EGFR mutant NSCLC patients who have failed first-line EGFR TKI: KCSG-LU12-13.

Researchers

Presenter

  • Kwai Han Yoo

Principal Investigators

  • Ki Hyeong Lee

  • Keon Uk Park

  • Ki Hwan Kim

  • Eun Kyung Cho

  • Kyung A. Kwon

  • Heuijune Ahn

  • Hye Ryun Kim

  • Hoon-Gu Kim

  • Ha Yeon Lee

  • Hwan Jung Yun

  • Jin-Hyoung Kang

  • Jaeheon Jeong

  • Moon Young Choi

  • Sin-Ho Jung

  • Jong-Mu Sun

  • Jin Seok Ahn

  • Keunchil Park

  • Myung-Ju Ahn

Medical Centers

  • N/A

Locations

  • N/A

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Non Small Cell Lung cancer

Biomarkers

  • N/A

Drug/Treatment

  • Pemetrexed

  • Cisplatin

Outcome

  • Negative

Study Design

  • Randomized

  • Open Label

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved